Oxcarbazepine Suspension
Product Images NDC 85742-007

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 85742-007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kanchan Healthcare Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxcar-12 (Oxcar 12)

A Kaplan-Meier survival plot comparing time to exit (days) between two treatment groups labeled HIGH and LOW. The y-axis represents the exit rate from 0.0 to 1.0, and the x-axis represents time to exit in days, up to 130. The plot includes a log-rank test p-value of 0.0001 indicating statistical comparison between groups.*

FDA Label Image

Oxcar-14 (Oxcar 14)

Oxcarbazepine oral suspension 300 mg/5 mL in a single-dose cup vial. The image shows a sealed plastic cup designed for oral use, typically used for individual doses of liquid medication. The labeler is Kanchan Healthcare Inc.*

FDA Label Image

Oxcar-15 (Oxcar 15)

Packaging image of Oxcarbazepine oral suspension bottle. The bottle is amber-colored with a white child-resistant cap. The image focuses on the container itself without visible labeling details such as strength, volume, or manufacturer text.*

FDA Label Image

Oxcar-16 (Oxcar 16)

An instructional illustration of an oral syringe labeled with volume markings up to 10 mL. Two parts of the syringe are identified by arrows and labels: the barrel and the plunger. The image is likely used to demonstrate measurement and administration of liquid medication.*

FDA Label Image

Oxcar-17 (Oxcar 17)

An instructional illustration showing a hand holding a bottle and shaking it gently, indicating the proper way to mix or prepare the oral suspension prior to use.*

FDA Label Image

Oxcar-18 (Oxcar 18)

An instructional illustration showing hands opening or closing a bottle by pressing or pinching the top of the bottle's neck. The bottle is accompanied by a detached cap placed beside it. The image likely demonstrates how to safely open or close a suspension bottle.*

FDA Label Image

Oxcar-19 (Oxcar 19)

An instructional illustration showing a hand holding a bottle and shaking it, indicating the proper preparation step for an oral suspension medication.*

FDA Label Image

Oxcar-20 (Oxcar 20)

An instructional illustration showing a hand holding a syringe positioned above the opening of a bottle. Another hand steadies the bottle, with a downward arrow indicating insertion or withdrawal of liquid into the syringe. The image demonstrates how to draw suspension from a bottle, relevant to the oral suspension dosage form.*

FDA Label Image

Oxcar-21 (Oxcar 21)

An instructional line drawing showing a hand holding a measuring syringe connected to a bottle, with arrows indicating the motion of drawing liquid into the syringe from the bottle. The illustration demonstrates how to measure oral suspension medication accurately.*

FDA Label Image

Oxcar-22 (Oxcar 22)

An instructional illustration showing a person holding an oral suspension bottle upside down and using an oral syringe to measure a dose. A close-up inset highlights the 5 to 10 mL graduated markings on the syringe for accurate dosing.*

FDA Label Image

Oxcar-23 (Oxcar 23)

An instructional illustration depicting the correct use of a syringe to measure and withdraw liquid from a bottle, likely demonstrating how to prepare an oral suspension dose.*

FDA Label Image

Oxcar-24 (Oxcar 24)

An instructional illustration showing a person taking an oral medication suspension using a measuring syringe. The image also depicts liquid being drawn into the syringe from a measuring cup, demonstrating proper dosing technique for oral suspension medication.*

FDA Label Image

Oxcar-26 (Oxcar 26)

Label for Oxcarbazepine Oral Suspension USP, 300 mg/5 mL, 250 mL bottle by Kanchan Healthcare Inc. The label includes instructions to shake well before use, contains 300 mg oxcarbazepine per 5 mL, and storage information. Manufactured by Medley Pharmaceuticals Ltd, India, and distributed by Kanchan Healthcare Inc, USA.*

FDA Label Image

Oxcarb-10 (Oxcarb 10)

A Kaplan-Meier survival curve showing seizure rates over days from first dose to first seizure, comparing treatment groups of Oxcarbazepine suspension and placebo. The y-axis represents seizure rate, and the x-axis represents days. The graph includes a log-rank test p-value of 0.046 indicating statistical comparison between groups.*

FDA Label Image

Oxcarb-11 (Oxcarb 11)

A survival curve chart showing the time to exit over days for two treatment groups labeled HIGH and LOW. The y-axis represents exit rate from 0 to 1.0, and the x-axis represents time to exit in days, ranging from 0 to 130. The chart includes a p-value of 0.0001 from a log-rank test comparing the two groups.*

FDA Label Image

Oxcarbazepine-9 (Oxcarb 9)

A Kaplan-Meier survival plot showing exit rates over time from day 2 to day 11, comparing treatment groups Oxcarbazepine and Placebo. The graph includes a log-rank test p-value of 0.0001 indicating statistical comparison between the groups.*

FDA Label Image

Oxcarbazepine-fig1 (Oxcarbazepine 1)

A dosage table showing weight in kilograms with corresponding starting and maximum dose ranges in milligrams per day for a medication. The table lists weights from 20 kg to 70 kg and associated dose ranges from 600 mg/day to 2100 mg/day.*

FDA Label Image

Oxcarbazepine-25 (Oxcarbazepine 25)

Label for Oxcarbazepine Oral Suspension USP 300 mg/5 mL, a 250 mL oral suspension. The label includes the NDC 85742-007-06 and is manufactured by Medley Pharmaceuticals Ltd and Kanchan Healthcare Inc. It instructs to shake well before use, contains dosage details, storage instructions, and pharmacist dispensing guidance.*

FDA Label Image

Oxcarbazepine-7 (Oxcarbazepine 7)

Chemical structure of oxcarbazepine, showing its molecular framework with a ketone group and an amide side group attached to a dibenzazepine ring system.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.